Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor class drugs
2 results
Jesduvroq (daprodustat)
(daprodustat)GlaxoSmithKline LLC
Usage: JESDUVROQ is indicated for treating anemia due to chronic kidney disease in adults on dialysis for at least four months. It is not intended for improving quality of life, nor for use as a substitute for red blood cell transfusions or in non-dialysis patients with anemia.
Vafseo (vadadustat)
(Vadadustat)Akebia Therapeutics, Inc.
Usage: VAFSEO is indicated for treating anemia in adults with chronic kidney disease who have been on dialysis for at least three months. It is not approved for improving quality of life or for patients not on dialysis. It should not replace red blood cell transfusions for urgent anemia correction.